Articles From: Hennes & Mauritz October Sales +14% to Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting


2014/11/17
By Jens Hansegard STOCKHOLM--Swedish clothing retailer Hennes & Mauritz (HM-B.SK) Monday reported 14% higher sales in October than in the same month last year.
Sign-up for Hennes & Mauritz October Sales +14% investment picks
2014/11/17
By Andrew Morse ZURICH --
Sign-up for More Than Three-Quarters of Nobel Biocare Shares Committed to Buyout Offer investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159279&ProfileId=051205&sourceType=1 BAIE VERTE, NL --
Sign-up for Rambler and Maritime Agree to Evaluate the Viability of Restarting the Past Producing Hammerdown Gold Mine investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159289&ProfileId=051205&sourceType=1 ABERDEENSHIRE, UNITED KINGDOM --
Sign-up for Xcite Energy Limited Memorandum of Understanding With China Oilfield Services Limited investment picks
SEATTLE , Nov.
Sign-up for CTI BioPharma to Present at the Upcoming Investor Conferences investment picks
2014/11/16
By P.R. Venkat Singapore conglomerate Keppel Corp.'s unit, which is looking to raise over 500 million Singapore dollars (US$400 million) in an initial public offering of its data centers, has secured about 10 cornerstone investors for the deal, people with knowledge of the matter said Monday.
Sign-up for Keppel Unit Secures Key Investors for IPO investment picks
2014/11/16
By Qu Yunxu BEIJING (Caixin Online) -- Alibaba Group Holding Ltd.'s (BABA) annual e-commerce frenzy smashed last year's record, but company executives were not exactly ecstatic.
Sign-up for Alibaba and the truth behind the Singles Day sales numbers investment picks
2014/11/16
By Matt Wirz Ukraine's deputy prime minister was in a bind when he came to the San Mateo, Calif., office of mutual-fund manager Michael Hasenstab in January 2013.
Sign-up for Michael Hasenstab Bets Big in Controversial Places investment picks
2014/11/16
He made a huge profit as Ireland and Poland muddled through the crisis--and gained a reputation among government leaders as a white-knight investor.
Sign-up for Michael Hasenstab Bets Big in Controversial Places -2- investment picks
2014/11/16
By Gregor Stuart Hunter Investors poured money into China's stock market Monday on the first day of trading in a program that opened up the country's markets to trading through Hong Kong.
Sign-up for Money Surges Into Shanghai Stocks on Stock Connect's First Day -- Update investment picks
AUSTIN, Texas , Nov.
Sign-up for Hanger Postpones Release of Third Quarter 2014 Financial Results investment picks
2014/11/16
By Jonathan D.
Sign-up for Allergan, Actavis Near Deal -- 3rd Update investment picks
2014/11/16
By Christopher Mims The Web--that thin veneer of human-readable design on top of the machine babble that constitutes the Internet--is dying.
Sign-up for The Web Is Dying; Apps Are Killing It investment picks
2014/11/16
By Chelsey Dulaney And Paul Ziobro Nearing the one-year anniversary of Target Corp.'s massive and costly data breach, the company is looking to show that it has moved on.
Sign-up for Target Finishes Licking Its Wounds investment picks
-Only Rentrak Provides the Official Global Movie Results- LOS ANGELES , Nov.
Sign-up for Rentrak Announces Official Worldwide Box Office Results for Weekend of November 16, 2014 investment picks
2014/11/16
By Jonathan D.
Sign-up for Allergan, Actavis Near Deal -- 2nd Update investment picks
2014/11/16
By Daniel Gilbert In its effort to force a merger on Baker Hughes Inc. by replacing its board, Halliburton Co.
Sign-up for For Halliburton, Replacing Baker Board May Not Be Easy investment picks
Botox maker Allergan Inc. (AGN) and Irish pharmaceutical company Actavis PLC (ACT) are close to a friendly deal, which could be announced as early as Monday, the Wall Street Journal reported Sunday.
Sign-up for Allergan, Actavis near cash-and-stock deal: WSJ investment picks
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol.
Sign-up for AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting investment picks
2014/11/16
By Esther Fung SHANGHAI--Chinese property developer Evergrande Real Estate Group Ltd plans to invest around HK$950 million ($122.5 million) for a controlling stake in a Hong Kong-based magazine publisher, New Media Group Holdings--its latest foray in a new business line as the firm looks to diversify to cushion the risks from a weakened property market.
Sign-up for China's Evergrande Group Buys Publisher as Diversification Continues investment picks
Months of dedication and hard work in science, technology, engineering and mathematics (STEM) paid off tonight for three students named National Finalists in the Siemens Competition in Math, Science & Technology, the nation’s premier research competition for high school students.
Sign-up for Arizona and New Mexico High School Scientists Win Regional Siemens Competition at the University of Texas at Austin for Research on Intrinsically Disordered Proteins for Drug Discovery and Computational Models of Tree Growth investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trading in Monday's session are Tyson Foods Inc., Urban Outfitters Inc. and Agilent Technologies Inc. Tyson Foods (TSN) is projected to post fiscal fourth-quarter earnings of 76 cents a share, according to a consensus survey by FactSet.
Sign-up for UPDATE: Tyson, Urban Outfitters, Agilent earnings in focus investment picks
2014/11/16
By Wallace Witkowski, MarketWatch Home Depot, Lowe's, Target report results SAN FRANCISCO (MarketWatch) -- Earnings season wraps up this week as the last Dow component and most of the remaining S&P 500 companies report.
Sign-up for MARKET SNAPSHOT: Retailers Close Out Earnings Season investment picks
2014/11/16
By Wallace Witkowski, MarketWatch Home Depot, Lowe's, Target report results SAN FRANCISCO (MarketWatch) -- Earnings season wraps up this week as the last Dow component and most of the remaining S&P 500 companies report.
Sign-up for UPDATE: Retailers close out earnings season investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced preliminary results from a phase 1 investigator-sponsored trial (IST) evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma.
Sign-up for Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib investment picks
2014/11/15
By Ryan Dezember Martin Craighead's ascent to the upper levels of Baker Hughes Inc.'s management came as the oilfield-service company swallowed a rival to better compete with larger companies Halliburton Co.
Sign-up for Baker Hughes Lifer Defends His Firm investment picks
- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome - LA JOLLA, Calif.
Sign-up for Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Hennes & Mauritz October Sales +14% to Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent